NCT03143712View on ClinicalTrials.gov

Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

June 14, 2017

Study Completion Date

June 14, 2017

Conditions

Healthy

Interventions

DRUG

GLPG1690

Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)

Trial Locations (1)

Unknown

SGS CPU, Antwerp

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Galapagos NV

INDUSTRY